$1.52 Earnings Per Share Expected for Merck & Co., Inc. (NYSE:MRK) This Quarter

Brokerages expect Merck & Co., Inc. (NYSE:MRK) to announce $1.52 earnings per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Merck & Co., Inc.’s earnings, with estimates ranging from $1.36 to $1.59. Merck & Co., Inc. posted earnings of $1.74 per share in the same quarter last year, which indicates a negative year-over-year growth rate of 12.6%. The firm is scheduled to issue its next quarterly earnings results before the market opens on Thursday, October 28th.

On average, analysts expect that Merck & Co., Inc. will report full-year earnings of $5.67 per share for the current fiscal year, with EPS estimates ranging from $5.47 to $6.49. For the next year, analysts expect that the firm will post earnings of $6.52 per share, with EPS estimates ranging from $6.10 to $8.00. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Merck & Co., Inc..

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Wednesday, July 28th. The company reported $1.31 EPS for the quarter, hitting analysts’ consensus estimates of $1.31. Merck & Co., Inc. had a return on equity of 50.93% and a net margin of 11.48%. The company had revenue of $11.40 billion for the quarter, compared to analysts’ expectations of $11.21 billion. During the same period in the prior year, the firm earned $1.37 earnings per share.

MRK has been the topic of a number of research reports. Berenberg Bank restated a “hold” rating and set a $92.00 price target (up from $86.00) on shares of Merck & Co., Inc. in a research note on Sunday. Truist began coverage on Merck & Co., Inc. in a research report on Tuesday, July 27th. They set a “buy” rating and a $92.00 price objective on the stock. Barclays increased their target price on Merck & Co., Inc. from $87.00 to $92.00 and gave the company an “overweight” rating in a report on Friday, October 8th. Zacks Investment Research raised Merck & Co., Inc. from a “sell” rating to a “hold” rating and set a $82.00 price objective on the stock in a report on Tuesday, August 24th. Finally, Morgan Stanley raised their price objective on Merck & Co., Inc. from $85.00 to $88.00 and gave the stock an “equal weight” rating in a report on Tuesday. Four equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $92.18.

Several large investors have recently bought and sold shares of the stock. Security National Bank lifted its holdings in shares of Merck & Co., Inc. by 6.8% during the 3rd quarter. Security National Bank now owns 84,779 shares of the company’s stock valued at $6,368,000 after acquiring an additional 5,366 shares in the last quarter. Canton Hathaway LLC lifted its holdings in shares of Merck & Co., Inc. by 9.8% during the 3rd quarter. Canton Hathaway LLC now owns 5,820 shares of the company’s stock valued at $437,000 after acquiring an additional 520 shares in the last quarter. Pacific Wealth Strategies Group Inc. lifted its holdings in shares of Merck & Co., Inc. by 3.1% during the 3rd quarter. Pacific Wealth Strategies Group Inc. now owns 18,277 shares of the company’s stock valued at $1,373,000 after acquiring an additional 552 shares in the last quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH lifted its holdings in Merck & Co., Inc. by 11.2% in the 3rd quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH now owns 9,020 shares of the company’s stock worth $678,000 after buying an additional 909 shares in the last quarter. Finally, Stock Yards Bank & Trust Co. lifted its holdings in Merck & Co., Inc. by 2.2% in the 3rd quarter. Stock Yards Bank & Trust Co. now owns 45,629 shares of the company’s stock worth $3,427,000 after buying an additional 967 shares in the last quarter. Institutional investors and hedge funds own 71.83% of the company’s stock.

NYSE:MRK traded down $0.24 during trading hours on Friday, reaching $78.71. 432,765 shares of the stock were exchanged, compared to its average volume of 12,310,182. The company has a quick ratio of 1.06, a current ratio of 1.31 and a debt-to-equity ratio of 0.72. The business has a 50-day moving average of $76.31 and a two-hundred day moving average of $76.75. Merck & Co., Inc. has a twelve month low of $70.89 and a twelve month high of $85.60. The company has a market capitalization of $199.24 billion, a price-to-earnings ratio of 36.08, a PEG ratio of 2.16 and a beta of 0.41.

The business also recently declared a quarterly dividend, which was paid on Thursday, October 7th. Shareholders of record on Wednesday, September 15th were issued a $0.65 dividend. The ex-dividend date was Tuesday, September 14th. This represents a $2.60 dividend on an annualized basis and a dividend yield of 3.30%. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 43.77%.

About Merck & Co., Inc.

Merck & Co, Inc engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

See Also: Investing in Growth Stocks

Get a free copy of the Zacks research report on Merck & Co., Inc. (MRK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.